Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 27 |
| Active Pipeline (Recruiting Now) | 21 (18) |
| Completed vs Stopped Early | 4 / 2 (7.4%) |
| Median Closed Actual Enrollment | 98 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Jilin Cancer Hospital | Changchun | 11 |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang | 10 |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 10 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07724366 | A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | Phase III | RECRUITING |
| NCT06452706 | The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Phase II | RECRUITING |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Can | Phase III | RECRUITING |
| NCT07406035 | A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | Phase II | RECRUITING |
| NCT07047365 | TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.